Use of eflornithine (DFMO) in the treatment of children with high-risk neuroblastoma
G. B. Sagoyan,
A. M. Suleymanova,
M. V. Rubanskaya,
R. Kh. Papyan,
K. I. Kirgizov,
S. R. Varfolomeeva https://doi.org/10.21682/2311-1267-2025-12-3-80-84
Abstract
Current approaches to treating high-risk neuroblastoma include surgery, chemotherapy, radiation therapy, bone marrow transplantation, and immunotherapy. Despite multimodal treatment, the prognosis for this group of patients remains poor: relapse of the underlying disease occurs in 50 % of cases, and over 90 % of these patients die. Therefore, developing effective strategies to prevent relapse is key to improving long-term outcomes. The article presents a review of the use of the drug eflornithine (DFMO) in the treatment of children with high-risk neuroblastoma.
Supporting agencies: The study was performed without external funding
About the Authors
G. B. Sagoyan
N.N. Blokhin National Medical Research Centre of Oncology, Ministry of Health of Russia
Russian Federation
Russian Federation
Senior Researcher, Pediatric Oncologist Pediatric Oncology Department No 1 (Chemotherapy of Tumors of Thoracoabdominal Localization) of the Research Institute of Pediatric Oncology and Hematology named after Academician of the Russian Academy of Medical Sciences L.A. Durnov at N.N. Blokhin National Medical Research Center of Oncology, MHR.
23 Kashirskoe Shosse, Moscow, 115522
A. M. Suleymanova
N.N. Blokhin National Medical Research Centre of Oncology, Ministry of Health of Russia
Russian Federation
Russian Federation
Senior Researcher, Pediatric Oncologist Pediatric Oncology Department No 1 (Chemotherapy of Tumors of Thoracoabdominal Localization) of the Research Institute of Pediatric Oncology and Hematology named after Academician of the Russian Academy of Medical Sciences L.A. Durnov at N.N. Blokhin National Medical Research Center of Oncology, MHR.
23 Kashirskoe Shosse, Moscow, 115522
M. V. Rubanskaya
N.N. Blokhin National Medical Research Centre of Oncology, Ministry of Health of Russia
Russian Federation
Russian Federation
Cand. of Sci. (Med.), Head of the Pediatric Oncology Department No 1 (Chemotherapy of Tumors of Thoracoabdominal Localization) of the Research Institute of Pediatric Oncology and Hematology named after Academician of the Russian Academy of Medical Sciences L.A. Durnov at N.N. Blokhin National Medical Research Center of Oncology, MHR.
23 Kashirskoe Shosse, Moscow, 115522
R. Kh. Papyan
Immune Oncology Research Institute; Pediatric Cancer and Blood Disorders Center of Armenia, Yeolyan Hematology and Oncology Center; Yerevan State Medical University
Armenia
Armenia
Head of the Pediatric Oncology Department at the Yeolyan Hematology and Oncology Center, Pediatric Director, Senior Researcher at the Immune Oncology Research Institute, Head of the Pediatric Oncology Department at the Hematology Center named after Professor R.O. Yeolyan, Lecturer at the Department of Pediatric Oncology and Hematology at the Yerevan State Medical University, Co-chair of Global Health Network Adolescents and Young Adults Working Group of SIOP.
7 Nersisyan St., Yerevan, 0014; 7 Nersisyan St., Yerevan, 0014; 2 Koryun St., Yerevan, 0025
K. I. Kirgizov
N.N. Blokhin National Medical Research Centre of Oncology, Ministry of Health of Russia
Russian Federation
Russian Federation
Cand. of Sci. (Med.), Deputy Director for Scientific Work of Research Institute of Pediatric Oncology and Hematology named after Academician of the Russian Academy of Medical Sciences L.A. Durnov at N.N. Blokhin National Medical Research Center of Oncology, MHR.
23 Kashirskoe Shosse, Moscow, 115522
S. R. Varfolomeeva
N.N. Blokhin National Medical Research Centre of Oncology, Ministry of Health of Russia
Russian Federation
Russian Federation
Dr. of Sci. (Med.), Professor, Director of the Research Institute of Pediatric Oncology and Hematology named after Academician of the Russian Academy of Medical Sciences L.A. Durnov at N.N. Blokhin National Medical Research Center of Oncology, MHR.
23 Kashirskoe Shosse, Moscow, 115522
References
1. Irwin M.S., Park J.R. Neuroblastoma: paradigm for precision medicine. Pediatr Clin North Am. 2015;62(1):225–56. doi: 10.1016/j.pcl.2014.09.015. PMID: 25435121.
2. Berthold F., Boos J., Burdach S., Erttmann R., Henze G., Hermann J., Klingebiel T., Kremens B., Schilling F.H., Schrappe M., Simon T., Hero B. Myeloablative megatherapy with autologous stem-cell rescue versus oral maintenance chemotherapy as consolidation treatment in patients with high-risk neuroblastoma: a randomised controlled trial. Lancet Oncol. 2005;6(9):649–58. doi: 10.1016/S1470-2045(05)70291-6. PMID: 16129365.
3. Cheung N.K., Cheung I.Y., Kushner B.H., Ostrovnaya I., Chamberlain E., Kramer K., Modak S. Murine anti-GD2 monoclonal antibody 3F8 combined with granulocyte-macrophage colony-stimulating factor and 13-cis-retinoic acid in high-risk patients with stage 4 neuroblastoma in fi rst remission. J Clin Oncol. 2012 Sep 10;30(26):3264-70. doi: 10.1200/JCO.2011.41.3807. Epub 2012 Aug 6. PMID: 22869886; PMCID: PMC3434986.
4. Pinto N.R., Applebaum Mark.A., Volchenboum S.L., Matthay K.K., London W.B., Ambros P.F., Nakagawara A., Berthold F., Schleiermacher G., Park J.R., Valteau-Couanet D., Pearson A.D.J., Cohn S.L. Advances in Risk Classifi cation and Treatment Strategies for Neuroblastoma. J Clin Oncol. 2015;33(27):3008–17. doi: 10.1200/JCO.2014.59.4648.
5. Yu A.L., Gilman A.L., Ozkaynak M.F., London W.B., Kreissman S.G., Chen H.X., Smith M., Anderson B., Villablanca J.G., Matthay K.K., Shimada H., Grupp S.A., Seeger R., Reynolds C.P., Buxton A., Reisfeld R.A., Gillies S.D., Cohn S.L., Maris J.M., Sondel P.M.; Children's Oncology Group. Anti-GD2 antibody with GM-CSF, interleukin-2, and isotretinoin for neuroblastoma. N Engl J Med. 2010;363(14):1324–34. doi: 10.1056/NEJMoa0911123. PMID: 20879881; PMCID: PMC3086629.
6. Yu A., Gilman A. L., Ozkaynak F.M., Sondel P.M., Cretella S., Diccianni M., Cohn S.L., Maris J.M., Smith M.A., Park J.R. Update of outcome for high-risk neuroblastoma treated on a randomized trial of chimeric Anti-GD2 antibody (ch14.18) + GM-CSF/IL2 immunotherapy in 1st response: A Children’s Oncology Group Study. Advances in Neuroblastoma Research Association. 2014. Abstract No. PL013, р. 108.
7. London W.B., Bagatell R., Weigel B.J., Fox E., Guo D., van Ryn C., Naranjo A., Park J.R. Historical time to disease progression and progression-free survival in patients with recurrent/refractory neuroblastoma treated in the modern era on Children's Oncology Group early-phase trials. Cancer. 2017;123(24):4914–23. doi: 10.1002/cncr.30934. Epub 2017 Sep 8. PMID: 28885700; PMCID: PMC5716896.
8. Meyskens F.L. Jr, Gerner E.W. Development of difl uoromethylornithine (DFMO) as a chemoprevention agent. Clin Cancer Res. 1999;5(5):945–51. PMID: 10353725.
9. Geerts D., Koster J., Albert D., Koomoa D.L., Feith D.J., Pegg A.E., Volckmann R., Caron H., Versteeg R., Bachmann A.S. The polyamine metabolism genes ornithine decarboxylase and antizyme 2 predict aggressive behavior in neuroblastomas with and without MYCN amplifi cation. Int J Cancer. 2010;126(9):2012–24. doi: 10.1002/ijc.25074. PMID: 19960435; PMCID: PMC2847573.
10. Rounbehler R.J., Li W., Hall M.A., Yang C., Fallahi M., Cleveland J.L. Targeting ornithine decarboxylase impairs development of MYCNamplifi ed neuroblastoma. Cancer Res. 2009;69(2):547–53. doi: 10.1158/0008-5472.CAN-08-2968. PMID: 19147568; PMCID: PMC2749594.
11. Gamble L.D., Hogarty M.D., Liu X., Ziegler D.S., Marshall G., Norris M.D., Haber M. Polyamine pathway inhibition as a novel therapeutic approach to treating neuroblastoma. Front Oncol. 2012;2:162. doi: 10.3389/fonc.2012.00162. PMID: 23181218; PMCID: PMC3499881.
12. Chang T.C., Zeitels L.R., Hwang H.W., Chivukula R.R., Wentzel E.A., Dews M., Jung J., Gao P., Dang C.V., Beer M.A., Thomas-Tikhonenko A., Mendell J.T. Lin-28B transactivation is necessary for Myc-mediated let-7 repression and proliferation. Proc Natl Acad Sci U S A. 2009;106(9):3384–9. doi: 10.1073/pnas.0808300106. Epub 2009 Feb 11. PMID: 19211792; PMCID: PMC2651245.
13. Molenaar J.J., Domingo-Fernández R., Ebus M.E., Lindner S., Koster J., Drabek K., Mestdagh P., van Sluis P., Valentijn L.J., van Nes J., Broekmans M., Haneveld F., Volckmann R., Bray I., Heukamp L., Sprüssel A., Thor T., Kieckbusch K., Klein-Hitpass L., Fischer M., Vandesompele J., Schramm A., van Noesel M.M., Varesio L., Speleman F., Eggert A., Stallings R.L., Caron H.N., Versteeg R., Schulte J.H. LIN28B induces neuroblastoma and enhances MYCN levels via let-7 suppression. Nat Genet. 2012;44(11):1199–206. doi: 10.1038/ng.2436. Epub 2012 Oct 7. PMID: 23042116.
14. Cherkaoui S., Yang L., McBride M., Turn C.S., Lu W., Eigenmann C., Allen G.E., Panasenko O.O., Zhang L., Vu A., Liu K., Li Y., Gandhi O.H., Surrey L., Wierer M., White E., Rabinowitz J.D., Hogarty M.D., Morscher R.J. Reprogramming neuroblastoma by diet-enhanced polyamine depletion. bioRxiv [Preprint]. 2024 Jan 8:2024.01.07.573662. doi: 10.1101/2024.01.07.573662. PMID: 38260457; PMCID: PMC10802427.
15. Evageliou N.F., Haber M., Vu A., Laetsch T.W., Murray J., Gamble L.D., Cheng N.C., Liu K., Reese M., Corrigan K.A., Ziegler D.S., Webber H., Hayes C.S., Pawel B., Marshall G.M., Zhao H., Gilmour S.K., Norris M.D., Hogarty M.D. Polyamine antagonist therapies inhibit neuroblastoma initiation and progression. Clin Cancer Res. 2016;22(17):4391–404. doi: 10.1158/1078-0432.CCR-15-2539. Epub 2016 Mar 24. PMID: 27012811.
16. Saulnier Sholler G.L., Gerner E.W., Bergendahl G., MacArthur R.B., VanderWerff A., Ashikaga T., Bond J.P., Ferguson W., Roberts W., Wada R.K., Eslin D., Kraveka J.M., Kaplan J., Mitchell D., Parikh N.S., Neville K., Sender L., Higgins T., Kawakita M., Hiramatsu K., Moriya S.S., Bachmann A.S. A Phase I trial of DFMO targeting polyamine addiction in patients with relapsed/refractory neuroblastoma. PLoS One. 2015;10(5):e0127246. doi: 10.1371/journal.pone.0127246. PMID: 26018967; PMCID: PMC4446210.
17. Hogarty M.D., Ziegler D.S., Franson A., Chi Y.Y., Tsao-Wei D., Liu K., Vemu R., Gerner E.W., Bruckheimer E., Shamirian A., Hasenauer B., Balis F.M., Groshen S., Norris M.D., Haber M., Park J.R., Matthay K.K., Marachelian A. Phase 1 study of high-dose DFMO, celecoxib, cyclophosphamide and topotecan for patients with relapsed neuroblastoma: a New Approaches to Neuroblastoma Therapy trial. Br J Cancer. 2024;130(5):788–97. doi: 10.1038/s41416-023-02525-2. Epub 2024 Jan 10. PMID: 38200233; PMCID: PMC10912730.
18. Sholler G.L.S., Ferguson W., Bergendahl G., Bond J.P., Neville K., Eslin D., Brown V., Roberts W., Wada R.K., Oesterheld J., Mitchell D., Foley J., Parikh N.S., Eshun F., Zage P., Rawwas J., Sencer S., Pankiewicz D., Quinn M., Rich M., Junewick J., Kraveka J.M. Maintenance DFMO increases survival in high risk neuroblastoma. Sci Rep. 2018;8(1):14445. doi: 10.1038/s41598-018-32659-w. PMID: 30262852; PMCID: PMC6160434.
19. Lewis E.C., Kraveka J.M., Ferguson W., Eslin D., Brown V.I., Bergendahl G., Roberts W., Wada R.K., Oesterheld J., Mitchell D., Foley J., Zage P., Rawwas J., Rich M., Lorenzi E., Broglio K., Berry D., Saulnier Sholler G.L. A subset analysis of a phase II trial evaluating the use of DFMO as maintenance therapy for high-risk neuroblastoma. Int J Cancer. 2020;147(11):3152–9. doi: 10.1002/ijc.33044. Epub 2020 May 24. PMID: 32391579; PMCID: PMC7586843.
20. Oesterheld J., Ferguson W., Kraveka J.M., Bergendahl G., Clinch T., Lorenzi E., Berry D., Wada R.K., Isakoff M.S., Eslin D.E., Brown V.I., Roberts W., Zage P., Harrod V.L., Mitchell D.S., Hanson D., Saulnier Sholler G.L. Efl ornithine as postimmunotherapy maintenance in highrisk neuroblastoma: externally controlled, propensity score-matched survival outcome comparisons. J Clin Oncol. 2024;42(1):90–102. doi: 10.1200/JCO.22.02875. Epub 2023 Oct 26. PMID: 37883734; PMCID: PMC10730038.
21. Ferguson W., Kraveka J.M., Bergendahl G., Moore A., Clinch T., Saulnier Sholler G. Survival outcomes in patients with high-risk neuroblastoma on efl ornithine (DFMO) maintenance: matched external control analysis at 7-year follow-up. Advances in Neuroblastoma Research Association. 2025. Abstract No. PP-181.
22. Macy M.E., Naranjo A., Zhang F.F., Acord M., Cash T., DuBois S.G., Haunani Foster J., Knight K.R., Hogarty M.D., Mody R., Morgenstern D.A., Parisi M.T., Pinto N., Reynolds C.P., Keyel M.E., Shulkin B.L., Simon Ziegler D., Bagatell R., Park J.R., Goldsmith K.C. A phase 2 randomized study of chemoimmunotherapy with or without efl ornithine (DFMO) in relapsed/refractory neuroblastoma: A Children’s Oncology Group (COG) report. J Clin Oncol. 2025;43(16 suppl). doi: 10.1200/JCO.2025.43.16_suppl.10001.
23. [Electronic resource]: https://www.nccn.org/professionals/physician_gls/pdf/neuroblastoma.pdf (accessed 03.09.2025).
Review
For citations:
Sagoyan G.B., Suleymanova A.M., Rubanskaya M.V., Papyan R.Kh., Kirgizov K.I., Varfolomeeva S.R. Use of eflornithine (DFMO) in the treatment of children with high-risk neuroblastoma. Russian Journal of Pediatric Hematology and Oncology. 2025;12(3):80-84. (In Russ.) https://doi.org/10.21682/2311-1267-2025-12-3-80-84
Views:
11
Email this article 